Business Context and Reporting Period
Company: SANUWAVE Health, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 5, 2013
Principal Office: Alpharetta, Georgia
Context: The filing serves as a Regulation FD disclosure to provide an update on the Company's clinical trial investigating the dermaPACE device for the treatment of diabetic foot ulcers.
Key Financial Metrics
This Form 8-K is a disclosure of a material event and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change reported is the issuance of an update regarding the clinical trial status of the dermaPACE device. No financial changes or comparative period data are included in this specific filing.
Guidance, Outlook, and Risks
Management Commentary: The Company provided an update on its clinical trial for the dermaPACE device. Detailed results or commentary are contained in the attached press release (Exhibit 99.1), which is incorporated by reference.
Risks and Contingencies: The filing notes that the information in Item 7.01 and the attached exhibit shall not be deemed "filed" for purposes of Section 18 of the Securities Act of 1934, nor incorporated by reference into other filings except as expressly set forth by specific reference.
Investor Verification Checklist
- Review the attached Press Release (Exhibit 99.1) for specific details on the clinical trial update.
- Verify the current status of the dermaPACE device development and regulatory pathway.
- Check subsequent filings for any financial impact resulting from the clinical trial progress.
- Confirm the Company's cash position and runway, as this filing does not disclose liquidity metrics.